Fibrocell Science, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on extinguishment of debt
Gain on sale of Agera
Stock issued to related party for exclusive channel collaboration agreement
Stock-based compensation expense
Warrant revaluation and other finance (income) expense
Warrant liability revaluation income
Deferred tax benefit
Derivative liability revaluation expense (income)
Loss on disposal or impairment of property and equipment
Depreciation and amortization
Provision for doubtful accounts
Amortization of debt issuance costs
Amortization of discount on convertible debt converted to common shares
Intangible asset impairment
Recovery of doubtful accounts
Loss on write-down of inventory
Decrease (increase) in operating assets:
Accounts receivable
Inventory
Prepaid expenses and other current assets
Other assets
Increase (decrease) in operating liabilities:
Accounts payable
Related party payable
Accrued expenses and deferred rent
Accrued interest payable
Deferred revenue
Miscellaneous other

Net cash used in operating activities
Cash flows from investing activities:
Purchase of property and equipment
Proceeds from the sale of Agera
Proceeds from the sale of property and equipment
Net cash used in investing activities

Cash flows from financing activities:
Debt issuance costs
Net proceeds from preferred stock
Proceeds from private placement
Proceeds from exercise of common warrants
Proceeds from exercise of pre-funded warrants
Payment of deferred offering costs
Proceeds from the exercise of stock options
Subscription received
Payments on insurance loan
Principal payments on note payable
Dividends paid on preferred stock
Principal payments on capital lease obligations
Net cash provided by financing activities

Net decrease in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Noncash Investing and Financing Items
Property and equipment in accounts payable
Offering costs in accounts payable and accrued expenses
Reduction of warrant liability upon cashless exercise of warrants
Reduction of accrued interest payable upon cashless exercise of promissory notes
Reduction in derivative liability upon cashless exercise of promissory notes
Cashless exercise of promissory notes
Dividend paid in-kind to preferred stockholders
Deemed dividend on preferred stock

Comments